NRx Pharmaceuticals reported a third-quarter loss of $0.05 per share, well ahead of the -$0.29 consensus, an 82.8% surprise. Earnings improved 72.2% year over year as the net loss narrowed to $2.2 million from $5.9 million. Revenue was the weak spot. Net patient service revenue of $1.16 million rose 378.9% from a tiny base but missed the $1.35 million consensus by 14.1%. The quarter's real news was regulatory: the FDA approved preservative-free ketamine, the company's first drug, and management is now calling NRx a commercial-stage company. The central tension is that the business is spending and burning cash at a faster rate, while the bottom-line beat makes the quarter look healthier than the operations do.
The quality of the beat deserves scrutiny. Operating loss roughly doubled to $8.1 million from $4.0 million. SG&A climbed to $6.6 million from $2.8 million to prepare for the ketamine launch, and R&D rose to $1.8 million from $1.4 million. The roughly $6 million gap between the operating loss and the much smaller net loss therefore came from items below the operating line, which the release does not break out. For the nine-month period, the operating loss widened to $19.4 million from $11.6 million. The sales growth still came entirely from the HOPE Therapeutics clinics, which grew to six Florida locations from five last quarter, not from ketamine. Product shipments are not scheduled to begin until no later than January 2027.
The conference call preserved a credible platform story, and management's tone was clearly more confident. Several developments support that tone:
- **Product and manufacturing:** The blow-fill-seal luer-lock vial is described as a first-of-its-kind approval. Management estimates cost of goods at about $0.75 per unit versus roughly $3.25 for glass, and the company bought two blow-fill-seal machines to lock in manufacturing capacity.
- **Commercial launch:** A 17-person sales force is calling on hospitals and group purchasing organizations, and the first order arrived the day before the call, though management declined to disclose its size.
- **Non-dilutive funding:** The DARPA SPARC-TMS prime contract moved from negotiation to a signed award of about $11.25 million, with the first two invoices approved for fourth-quarter payment.
- **Pipeline:** New items include the NRX-200 subcutaneous ketamine program and a Yale/PCORI collaboration that management believes can supply confirmatory evidence for an accelerated-approval path for NRX-100.
Bears have legitimate ammunition, however, because many forward markers moved backward:
- **Market size:** The ketamine opportunity was restated to about $400 million from the $750 million cited on prior calls. Even the growth rate is inconsistent: the release cites 15% in one place and more than 15% in another, while the call cited about 17%.
- **NRX-100:** Earlier plans targeted a data package by mid-2026 and a possible decision by early 2027. The plan is now a rolling NDA by year-end with approval targeted in 2027.
- **Profitability:** The earlier goal of pro forma profitability by the end of 2026 has become an aim to demonstrate profitability in 2027.
- **SPARC-TMS:** The trial slid from a summer 2026 start to 2027 enrollment, with a readout in early 2028.
- **Clinic expansion:** Multi-state HOPE expansion plans were not reiterated.
- **Commercial strategy:** Management had previously said a hospital sales force was unlikely, and that reversal helps explain the SG&A jump.
The balance sheet frames the risk. Cash fell to $19.8 million from $26.7 million at the end of the second quarter, roughly $7 million of quarterly burn. That leaves something under three quarters of cushion at the current pace, before any ketamine revenue, DARPA payments, or further at-the-market share sales. The company has no convertible debt, and management upgraded its runway language to the "foreseeable future." Still, continued reliance on the at-the-market facility means dilution remains part of the funding model. The June offering raised about $22.3 million gross.
Investors were already skeptical heading into the report. Earnings Whispers sentiment weakened from -0.21 to -0.37, a meaningful move further into negative territory. The stock has fallen 36.2% from the $3.37 open after the August report to $2.15, about 27.6% below its 200-day moving average of $2.97. Price and AVWAP trend readings are both negative. The market has been discounting the approval story well before the commercial results can test it.
The bottom line is that NRx crossed a genuine threshold with its first FDA approval and a funded DARPA program, but the quarter's EPS beat rests on below-the-line items rather than operating improvement. Revenue missed, costs doubled, and nearly every timeline and market-size estimate moved the wrong way. The next several quarters must show actual ketamine order volume and a narrowing cash burn before the commercial transition looks like more than a reset of expectations.